ArticleFrontiers in medicine2026
Electroacupuncture as an adjunctive therapy for drug-refractory primary open-angle glaucoma: a CARE-compliant case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary open-angle glaucoma (POAG) is a progressive optic neuropathy; elevated intraocular pressure (IOP) is the only broadly modifiable risk factor. Some elderly patients remain uncontrolled on multi-drug regimens and are not immediate candidates for laser or filtering surgery. This CARE-compliant case report describes an integrative approach in such a patient. Case presentation: This case describes a 76-year-old woman with drug-refractory POAG and fluctuating IOP despite quadruple topical therapy. Adjunct electroacupuncture (EA, twice weekly) was initiated on March 28, 2025. IOP decreased from 12 mmHg in the right eye (OD) / 29 mmHg in the left eye (OS) to within target after the first two sessions and remained stable; best-corrected visual acuity (BCVA) improved from 0.4 (OD) / 0.25 (OS) to 0.5 in both eyes (OU). No major adverse events were observed. The observed clinical course was consistent with previously reported short-term IOP-lowering and ocular-perfusion effects of acupuncture in POAG. Conclusion: EA layered on top of standard care may be a feasible adjunct for short-term IOP stabilization and symptomatic improvement in drug-refractory POAG. However, given that topical antiglaucoma therapy was continued throughout the intervention and the inherent limitations of a single-case design, causal attribution cannot be established, and confirmation in randomized sham-controlled trials with longer follow-up is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.